CA Patent

CA2572223C — Angiogenesis inhibitors

Assigned to Johns Hopkins University · Expires 2014-08-12 · 12y expired

What this patent protects

Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.

USPTO Abstract

Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.

Drugs covered by this patent

Patent Metadata

Patent number
CA2572223C
Jurisdiction
CA
Classification
—
Expires
2014-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Johns Hopkins University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.